Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility

Journal of Clinical Microbiology

Volumn 52, Issue 11, 2014, Pages 4056-4057

  Streicher, Elizabeth M ^a   Maharaj, Kashmeel ^b   York, Talita ^a   Van Heerden, Carel ^a   Barnard, Marinus ^a   Diacon, Andreas ^a   Mendel, Carl M ^c   Bosman, Marlein E ^d   Hepple, Juli A ^a   Pym, Alexander S ^b   Warren, Robin M ^a   Van Helden, Paul D ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c TB Alliance   (United States)

^d NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZINAMIDE; AMIDASE; PNCA PROTEIN, MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSTATIC AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DNA EXTRACTION; DNA SEQUENCE; GENOTYPE PHENOTYPE CORRELATION; HIGH RESOLUTION MELTING ANALYSIS; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NONSYNONYMOUS MUTATION; PNCA GENE; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SPUTUM SMEAR; SYNONYMOUS MUTATION; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; EVALUATION STUDY; GENETICS; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; MICROBIAL SENSITIVITY TEST; MUTATION; PROCEDURES; TIME;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; GENOTYPING TECHNIQUES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM TUBERCULOSIS; PYRAZINAMIDE; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; TIME FACTORS;

EID: 84908337495     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02438-14     Document Type: Article

References (13)

1. World Health Organization. 2008. Policy guidance on drugsusceptibility testing (DST) of second-line antituberculosis drugs. World Health Organization, Geneva, Switzerland. http://whqlibdoc.who.int/hq/2008/WHO-HTM-TB-2008.392-eng.pdf.
2. Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. 2010. Potential for erroneous results indicating resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide. J. Clin. Microbiol. 48:300-301. http://dx.doi.org/10.1128/JCM.01775-09.
3. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat. Med. 2:662-667. http://dx.doi.org/10.1038/nm0696-662.
4. Hirano K, Takahashi M, Kazumi Y, Fukasawa Y, Abe C. 1997. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. Tuber. Lung Dis. 78:117-122.
5. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. 2009. Tuberculosis drug resistance mutation database. PLoS Med. 6(2):e2. http://dx.doi.org/10.1371/journal.pmed.1000002.
6. Cui Z, Wang J, Lu J, Huang X, Zheng R, Hu Z. 2013. Evaluation of methods for testing the susceptibility of clinical Mycobacterium tuberculosis isolates to pyrazinamide. J. Clin. Microbiol. 51:1374-1380. http://dx.doi.org/10.1128/JCM.03197-12.
7. Huang TS, Lee SS, Tu HZ, Huang WK, Chen YS, Huang CK, Wann SR, Lin HH, Liu YC. 2003. Correlation between pyrazinamide activity and pncA mutations in Mycobacterium tuberculosis isolates in Taiwan. Antimicrob. Agents Chemother. 47:3672-3673. http://dx.doi.org/10.1128/AAC.47.11.3672-3673.2003.
8. Mphahlele M, Syre H, Valvatne H, Stavrum R, Mannsaker T, Muthivhi T, Weyer K, Fourie PB, Grewal HM. 2008. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J. Clin. Microbiol. 46:3459-3464. http://dx.doi.org/10.1128/JCM.00973-08.
9. Louw GE, Warren RM, Donald PR, Murray MB, Bosman M, van Helden PD, Young DB, Victor TC. 2006. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int. J. Tuberc. Lung Dis. 10:802-807.
10. Jnawali HN, Hwang SC, Park YK, Kim H, Lee YS, Chung GT, Choe KH, Ryoo S. 2013. Characterization of mutations in multi- and extensive drug resistance among strains of Mycobacterium tuberculosis clinical isolates in Republic of Korea. Diagn. Microbiol. Infect. Dis. 76:187-196. http://dx.doi.org/10.1016/j.diagmicrobio.2013.02.035.
11. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, III, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632. http://dx.doi.org/10.1126/science.1208813.
12. Simons SO, Mulder A, van IJ, Boeree MJ, Van SD. 2013. Role of rpsA gene sequencing in diagnosis of pyrazinamide resistance. J. Clin. Microbiol. 51:382. http://dx.doi.org/10.1128/JCM.02739-12.
13. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: a review. Int. J. Tuberc. Lung Dis. 7:6-21.